CCXI
Churchill Capital Corp XI Class A
stockNASDAQ
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 10.83 | 2026-10-14 | -4.57% | 4.332 |
| 1M | 13.58 | 2026-09-21 | -23.89% | 3.227 |
| 3M | 14.83 | 2026-07-21 | -30.31% | 2.685 |
| 6M | 10.29 | 2026-04-21 | +0.44% | 1.827 |
| 1Y | 10.26 | 2026-02-09 | +0.73% | 1.083 |
| 5Y | 35.01 | 2021-10-21 | -70.48% | 0.080 |
Churchill Capital Corp XI Class A (NASDAQ:CCXI) stock price today is $10.34, and today's volume is 1,966,138. CCXI is down 0.193% today. The 30 day average volume is 2.59M. CCXI market cap is $575.66M with 55.70M shares outstanding.